Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 23326902)

1.

Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer [Internet].

Black ER, Falzon L, Aronson N.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Dec.

2.
3.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.

4.

Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.

Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S.

Cancer Prev Control. 1997 Dec;1(5):379-92.

PMID:
9765760
6.

A systematic overview of chemotherapy effects in colorectal cancer.

Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):282-308. Review.

PMID:
11441937
7.

Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].

Lin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov.

8.

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Albain KS, Paik S, van't Veer L.

Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Review.

PMID:
19914534
9.

Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.

Ishiguro M, Mochizuki H, Tomita N, Shimada Y, Takahashi K, Kotake K, Watanabe M, Kanemitsu Y, Ueno H, Ishikawa T, Uetake H, Matsui S, Teramukai S, Sugihara K.

BMC Cancer. 2012 Jul 7;12:281.

10.

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG.

J Clin Oncol. 2004 Aug 15;22(16):3408-19. Epub 2004 Jun 15. Review.

PMID:
15199089
11.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
12.

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.

Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB, Phillips KA.

Breast Cancer Res Treat. 2011 Nov;130(2):619-26. doi: 10.1007/s10549-011-1628-6. Epub 2011 Jun 17.

13.

Patients' perceptions of gene expression profiling in breast cancer treatment decisions.

Bombard Y, Rozmovits L, Trudeau ME, Leighl NB, Deal K, Marshall DA.

Curr Oncol. 2014 Apr;21(2):e203-11. doi: 10.3747/co.21.1524.

14.

Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis.

Lu AT, Salpeter SR, Reeve AE, Eschrich S, Johnston PG, Barrier AJ, Bertucci F, Buckley NS, Salpeter EE, Lin AY.

Clin Colorectal Cancer. 2009 Oct;8(4):207-14. doi: 10.3816/CCC.2009.n.035. Review.

PMID:
19822511
15.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

16.

Evolving role of gene expression signatures as biomarkers in early-stage colon cancer.

Goel G.

J Gastrointest Cancer. 2014 Dec;45(4):399-404. doi: 10.1007/s12029-014-9634-7.

PMID:
24989938
17.

Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.

Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK.

Cancer Prev Control. 1997 Dec;1(5):366-78.

PMID:
9765759
18.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

19.

Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?

Kelley RK, Venook AP.

Clin Colorectal Cancer. 2011 Jun;10(2):73-80. doi: 10.1016/j.clcc.2011.03.001. Epub 2011 Apr 22. Review.

20.

Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin [Internet].

Meleth S, Whitehead N, Evans TS, Lux L.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk